Denmark-based medical foundation Novo, which invests $300m per year through its corporate venturing funds, has reinvested in US-based drugs company Logical Therapeutics’ in its third round of funding.
Logical raised $16.9m in its series C round led by venture capital firms SV Life Sciences (SVLS) and Novitas Capital and including merchant bank and VC Burrill & Company alongside Novo.
The four series C investors, along with Sigvion Capital and PA Early Stage Partners, which provided the seed…
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
